Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shwan Jalal

Cardiovascular Disease Gulfport, MS Medical Doctor

NPI 1558673384 CMS profile 70048

4300B W Railroad St, Gulfport, MS 39501

Open in the dashboard

General payments

$10,363

318 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shwan Jalal of Gulfport, MS is reported in the CMS Open Payments database as having received $10,363 across 318 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,100 55
2024 General $732 34
2023 General $234 11
2022 General $2,214 55
2021 General $2,704 70
2020 General $468 28
2019 General $2,911 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shwan Jalal
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Shwan Jalal were reported at $1,100. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Shwan Jalal Cardiovascular Disease median Middle half National median
2019 $2,911 $450 $127–$1,392 $163
2020 $468 $242 $77–$751 $114
2021 $2,704 $335 $101–$1,037 $132
2022 $2,214 $395 $121–$1,211 $149
2023 $234 $443 $136–$1,283 $160
2024 $732 $450 $136–$1,323 $164
2025 $1,100 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,068 6 payments
  2. Abbott Laboratories $1,857 35 payments
  3. Medtronic, Inc. $1,681 20 payments
  4. Abiomed $952 35 payments
  5. E.R. Squibb & Sons, L.L.C. $481 29 payments
  6. Janssen Pharmaceuticals, Inc $420 30 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $348 25 payments
  8. Novartis Pharmaceuticals Corporation $327 20 payments
  9. Pfizer Inc. $257 16 payments
  10. Merck Sharp & Dohme Corporation $244 12 payments
  11. Other $1,729 90 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,860 298 payments
  2. Travel and Lodging $4,382 18 payments
  3. Gift $75 1 payment
  4. Education $46 1 payment
Products named General payments · program years 2019–2025
  1. CROSSBOSS $2,051 5 payments
  2. HawkOne $1,569 12 payments
  3. ASSURITY $1,123 7 payments
  4. Impella $880 32 payments
  5. XARELTO $420 30 payments
  6. CAMZYOS $363 20 payments
  7. LifeVest $348 25 payments
  8. VERQUVO $306 15 payments
  9. ACCENT $205 1 payment
  10. ELIQUIS $199 13 payments
  11. Other $3,015 167 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 112 billing codes

Paid by Medicare

$448,380

Medicare's payments for the services billed

Medicare patients

1,901

Average age 75

Services billed

9,124

1,042 women, 859 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Ischemic heart disease 42%
Diabetes 38%
Heart failure 33%
Chronic kidney disease 33%
Atrial fibrillation 30%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $62
$62 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $57
$57 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $50
$50 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $29
$29 — —
ELIQUIS
  • PFIZER INC. $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record